Annah S Rolig

13PUBLICATIONS
57CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTissue engineeringInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 17, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.

|Apr 29, 2026
YB-1 inhibition suppresses osteosarcoma growth and reverses tumor immunosuppression.

|May 22, 2025
INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering.

|Apr 09, 2025
The response to anti-PD-1 and anti-LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming.

Annah S Rolig, Xiyu Peng, Elizabeth R Sturgill

|May 01, 2023
Characterization of murine lymphocyte activation and exhaustion markers by a 14-color flow cytometry panel.

Daniel C Rose, Annah S Rolig, William L Redmond

|Apr 21, 2022
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT.

Annah S Rolig, Daniel C Rose, Grace Helen McGee

Pageof 3

Frequent Collaborators

9 joint publications

William L Redmond

2 joint publications

Nisha Holay

1 joint publications

Emily Goers Sweeney

1 joint publications

Karen Guillemin